Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.

Wang, Min

Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma. [electronic resource] - Oncotarget Jul 2015 - 17958-67 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.4641 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Basic Helix-Loop-Helix Transcription Factors--genetics
Biomarkers, Tumor--blood
CD4 Lymphocyte Count
Case-Control Studies
China
Enzyme-Linked Immunosorbent Assay
Female
Humans
Interferon-gamma--blood
Interleukin-17--blood
Interleukins--blood
Male
Middle Aged
Multiple Myeloma--blood
Neoplasm Staging
Nuclear Receptor Subfamily 1, Group F, Member 3--genetics
Polymerase Chain Reaction
RNA, Messenger--metabolism
Receptors, Aryl Hydrocarbon--genetics
Remission Induction
T-Lymphocyte Subsets--drug effects
Th17 Cells--drug effects
Treatment Outcome
Interleukin-22